A review of rivastigmine: a reversible cholinesterase inhibitor (Q35177675)

6 August 2017

1 reference

title

A review of rivastigmine: a reversible cholinesterase inhibitor (English)

1 reference

6 August 2017

Bradley R Williams

1

1 reference

PubMed ID

12860489

6 August 2017

Arlette Nazarians

series ordinal

2

1 reference

PubMed ID

12860489

6 August 2017

Mark A Gill

series ordinal

3

1 reference

6 August 2017

1 June 2003

1 reference

6 August 2017

Clinical Therapeutics

1 reference

6 August 2017

25

1 reference

6 August 2017

6

1 reference

6 August 2017

1634-1653

1 reference

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Prevalence of dementia in old age: clinical diagnoses in subjects aged 95 years and older

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Dementia and Alzheimer disease incidence: a prospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

1 reference

7 January 2021

The cholinergic hypothesis of Alzheimer's disease: a review of progress

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Survival following a diagnosis of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Amyloid Protein and Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Transection of the oesophagus for bleeding oesophageal varices

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

1 reference

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

The Global Deterioration Scale for assessment of primary degenerative dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980160-1

7 January 2021

10.1016/S0149-2918(03)80160-1

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12860489